country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-183457

Copy Link Print Information

Cilobamine

Cilobamine is an orally active antidepressant and a dopamine/norepinephrine reuptake inhibitor. Cilobamine increases the levels of Aniline hydroxylase and cytochrome P-450 in rat liver. Cilobamine promotes hypertrophy of the smooth endoplasmic reticulum in rat liver hepatocytes, increases relative liver weight and recoverable microsomal protein. Cilobamine produces stimulant and anxiogenic effects, and does not inhibit monoamine oxidase. Cilobamine can be used in the research of depression.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 69429-84-1
Formel: C₁₇H₂₃Cl₂NO
Molecular Weight:328.28

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Cilobamine Chemical Structure

CAS. Nr.: 69429-84-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

In Vivo

Cilobamine (3-300 mg/kg; p.o.; daily; 4 days) dose-dependently induces hepatic drug-metabolizing enzymes in male Charles River CD rats, with significant induction of all measured parameters occurring at 100 and 300 mg/kg, and is approximately 12 times less potent than sodium phenobarbital at achieving 200% of control cytochrome P-450 and ethylmorphine N-demethylase activity levels, and 14 times less potent for aniline hydroxylase activity^[1].
Cilobamine (100 mg/kg; p.o.; daily; 4 days) induces hepatic drug-metabolizing enzymes and increases relative liver weight in female Charles River CD rats without altering recoverable microsomal protein^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Charles River CD (male, 150-210 g)^[1]
Dosage:

3 mg/kg; 10 mg/kg; 30 mg/kg; 100 mg/kg; 300 mg/kg; 100 mg/kg (time-course analysis)
Administration:

p.o.; daily; 4 days; daily; up to 4 days (time-course analysis)
Result:

Showed no significant changes in ethylmorphine N-demethylase activity, aniline hydroxylase activity, cytochrome P-450 content, relative liver weight, or recoverable microsomal protein compared to controls at 3 mg/kg.
Significantly increased ethylmorphine N-demethylase activity; showed no significant changes in aniline hydroxylase activity, cytochrome P-450 content, relative liver weight, or recoverable microsomal protein compared to controls at 10 mg/kg.
Significantly increased ethylmorphine N-demethylase and aniline hydroxylase activities; showed no significant changes in cytochrome P-450 content or relative liver weight; decreased recoverable microsomal protein compared to controls at 30 mg/kg.
Significantly increased ethylmorphine N-demethylase activity (8.43 nmol HCHO/min/mg microsomal protein), aniline hydroxylase activity (25.94 nmol p-aminophenol/hr/mg microsomal protein), cytochrome P-450 content (0.96 nmol/mg microsomal protein), and relative liver weight (5.25 g/100 g body weight; control: 4.40 g/100 g body weight) compared to controls; showed no change in recoverable microsomal protein compared to controls at 100 mg/kg.
Revealed prominent hypertrophy of the smooth endoplasmic reticulum in hepatocytes at 100 mg/kg.
Showed ethylmorphine N-demethylase activity peaked after 3 doses, aniline hydroxylase activity peaked after 2 doses, and cytochrome P-450 content plateaued after 2 doses, with slight declines in enzyme activities after subsequent doses during time-course analysis at 100 mg/kg.
Significantly increased ethylmorphine N-demethylase activity, aniline hydroxylase activity, cytochrome P-450 content, relative liver weight (5.63 g/100 g body weight), and recoverable microsomal protein (34.97 mg/g liver wet weight) compared to controls at 300 mg/kg.

Animal Model:

Charles River CD (female, 150-210 g)^[1]
Dosage:

100 mg/kg
Administration:

p.o.; daily; 4 days
Result:

Significantly increased ethylmorphine N-demethylase activity (3.35 nmol HCHO/min/mg microsomal protein), aniline hydroxylase activity (16.39 nmol p-aminophenol/hr/mg microsomal protein), cytochrome P-450 content (0.67 nmol/mg microsomal protein), and relative liver weight (4.06 g/100 g body weight) compared to controls.
Showed no change in recoverable microsomal protein compared to controls.

Chemical Information

CAS. Nr. 69429-84-1
Molecular Weight 328.28
Formel C₁₇H₂₃Cl₂NO
SMILES

ClC1=CC=C(C2(C(C3CCC2CC3)NC(C)C)O)C=C1Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Leeson GA, et al. Dose related induction of the drug metabolizing enzymes of rat liver by cilobamine. Fundam Appl Toxicol. 1984 Apr;4(2 Pt 1):261-9. [Content Brief]

[2]. Wager S, et al. Cilobamine in the treatment of atypical depression[J]. Human Psychopharmacology: Clinical and Experimental, 1988, 3(3): 201-205.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cilobamine

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

In Vivo

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bioz

Keywords

Your Recently Viewed Products

Cilobamine

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

In Vivo

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Cilobamine Related Classifications

HY-183457 Related Classifications

Bioz

Keywords

Your Recently Viewed Products